Aleksandra Blagojevic graduated from the University of Basel with a Master in Drug Sciences in 2021. Before starting her master’s thesis, she gained industry experience as an intern in the Global Technical Development of Synthetic Molecules at Roche, working in the division of Services & Systems.

She conducted her master’s thesis in the Molecular Pharmacy group at the University of Basel under the supervision of Prof. Daniel Ricklin, focusing on the development and analysis of novel complement pathway inhibitors inspired by parasitic proteins. In June 2021, she continued in the group as a PhD student, investigating parasitic immune evasion proteins and their potential for therapeutic complement inhibition.

In January 2025, Aleksandra transitioned to a postdoctoral researcher position in the Molecular Pharmacy group. Her research focuses on the development of novel complement inhibitors targeting the initiation pathways, with the goal of advancing therapeutic strategies for rare diseases.